ImageneBio, Inc. — Director's Dealing 2022

Jun 14, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2022-06-09

Reporting Person: Bonita David P (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-09	Stock Option (Right to Buy)	$4.85	A	13419	Acquired	2032-06-09	Common Stock (13419)	Direct

Footnotes

F1: This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director.